Stance Capital’s Colgate-Palmolive CL Stock Holding History

Stance Capital’s Portfolio CL Stock Details CL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-40	Closed	-$3.64K	–	94
2024 Q4	$3.64K	Buy	+40	New	+$3.82K	﹤0.01%	193

Other funds holding CL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Stance Capital's CL Position: Q1 2025 in Review

Stance Capital sold out of Colgate-Palmolive (CL) in Q1 2025, closing a stake of 40 shares — an estimated $3.64K sold.

Stance Capital first reported a position in CL in Q4 2024 and held it in 1 quarter. The position peaked at $3.64K in Q4 2024. 1,942 funds tracked by Wall St. Rank hold CL as of Q1 2025.

Stance Capital reported no remaining Colgate-Palmolive position as of Q1 2025 after selling out during the quarter.
Stance Capital sold 40 Colgate-Palmolive shares in Q1 2025, an estimated $3.64K.
Stance Capital first reported a position in Colgate-Palmolive in Q4 2024 and held it in 1 quarter.
Stance Capital's Colgate-Palmolive position peaked at $3.64K in Q4 2024.
1,942 funds tracked by Wall St. Rank held Colgate-Palmolive as of Q1 2025.

Based on Stance Capital's 13F filing for Q1 2025, filed 16 May 2025.